Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research report sent to investors on Monday,Benzinga reports. D. Boral Capital currently has a $13.00 price target on the stock.

Enlivex Therapeutics Stock Up 4.6 %

Shares of NASDAQ:ENLV opened at $1.13 on Monday. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.59. The company’s fifty day moving average is $1.12 and its 200 day moving average is $1.25. The stock has a market cap of $24.19 million, a PE ratio of -1.15 and a beta of 1.11.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds have recently bought and sold shares of ENLV. Renaissance Technologies LLC boosted its stake in Enlivex Therapeutics by 112.6% during the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares in the last quarter. Two Sigma Securities LLC purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $26,000. Finally, Millennium Management LLC purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $742,000. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.